By targeting the PI3K/Akt/mTOR pathway in tandem, these compounds may exhibit a synergistic inhibition, effectively amplifying their anti-cancer prowess and offering a novel treatment modality against ovarian cancer. Here, AKT1 is linked to ovarian carcinoma.